Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Rescue of mutant p53 transcription function by ellipticine

Abstract

The p53 tumor suppressor is frequently inactivated in tumors by point mutations in the DNA-binding domain, resulting in loss of sequence-specific DNA binding and transcription function. We present evidence that ellipticine can restore the transactivation function of several transfected p53 mutants (175 H, 248W, 249S, 273 H, 281G), resulting in the induction of p53-responsive genes (p21WAF1,MDM2) and activation of a p53-responsive luciferase reporter. Ellipticine also activates mutant p53 function in tumor cells expressing endogenous 194F, 233L, 241F, and 273C mutants. Treatment with ellipticine alters mutant p53 reactivity to conformation-sensitive Pab1620 and Pab240 antibodies and increases its sequence-specific DNA-binding activity in vivo. Finally, ellipticine activates mutant p53 and induces p21WAF1 and MDM2 expression in nude mouse tumor xenografts. These results demonstrate that ellipticine can restore transcription function to mutant p53. This property may contribute to the selectivity of ellipticine-derived compounds against tumor cell lines expressing mutant p53.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Abarzua P, LoSardo JE, Gubler ML and Neri A . (1995). Cancer Res., 55, 3490–3494.

  • Abarzua P, LoSardo JE, Gubler ML, Spathis R, Lu YA, Felix A and Neri A . (1996). Oncogene, 13, 2477–2482.

  • Barak Y, Juven T, Haffner R and Oren M . (1993). EMBO J., 12, 461–468.

  • Bargonetti J, Manfredi JJ, Chen X, Marshak DR and Prives C . (1993). Genes Dev., 7, 2565–2574.

  • Boyd KE, Wells J, Gutman J, Bartley SM and Farnham PJ . (1998). Proc. Natl. Acad. Sci. USA, 95, 13887–13892.

  • Brachmann RK, Yu K, Eby Y, Pavletich NP and Boeke JD . (1998). EMBO J., 17, 1847–1859.

  • Brown CR, Hong-Brown LQ and Welch WJ . (1997). J Clin. Invest., 99, 1432–1444.

  • Buzdar AU, Hortobagyi GN, Esparza LT, Holmes FA, Ro JS, Fraschini G and Lichtiger B . (1990). Oncology, 47, 101–114.

  • Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G . (2002). Nat. Med., 8, 282–288.

  • Cho Y, Gorina S, Jeffrey PD and Pavletich NP . (1994). Science, 265, 346–355.

  • Foster BA, Coffey HA, Morin MJ and Rastinejad F . (1999). Science, 286, 2507–2510.

  • Freedman DA, Epstein CB, Roth JC and Levine AJ . (1997). Mol. Med., 3, 248–259.

  • Froelich-Ammon SJ, Patchan MW, Osheroff N and Thompson RB . (1995). J. Biol. Chem., 270, 14998–15004.

  • Gannon JV, Greaves R, Iggo R and Lane DP . (1990). EMBO J., 9, 1595–1602.

  • Gouyette A, Huertas D, Droz JP, Rouesse J and Amiel JL . (1982). Eur. J. Cancer Clin. Oncol., 18, 1285–1292.

  • Haupt Y, Maya R, Kazaz A and Oren M . (1997). Nature, 387, 296–299.

  • Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R and Harris CC . (1994). Nucleic Acids Res., 22, 3551–3555.

  • Honda R, Tanaka and Yasuda H . (1997). FEBS Lett., 420, 25–27.

  • Kattan J, Durand M, Droz JP, Mahjoubi M, Marino JP and Azab M . (1994). Am. J. Clin. Oncol., 17, 242–245.

  • Kubbutat MHG, Jones SN and Vousden KH . (1997). Nature, 387, 299–303.

  • Midgley CA and Lane DP . (1997). Oncogene, 15, 1179–1189.

  • Ohnishi T, Ohnishi K, Wang X, Takahashi A and Okaichi K . (1999). Radiat. Res., 151, 498–500.

  • Peng Y, Chen L, Li C, Lu W and Chen J . (2001). J. Biol. Chem., 276, 40583–40590.

  • Pochampally R, Fodera B, Chen L, Lu W and Chen J . (1999). J. Biol. Chem., 274, 15271–15277.

  • Pochampally R, Li C, Lu W, Chen L, Luftig R, Lin J and Chen J . (2000). Biochem. Biophys. Res. Commun., 279, 1001–1010.

  • Rouesse J, Spielmann M, Turpin F, Le Chevalier T, Azab M and Mondesir JM . (1993). Eur. J. Cancer, 29A, 856–859.

  • Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC and Wiman KG . (1997). Nat. Med., 3, 632–638.

  • Shi LM, Myers TG, Fan Y, O'Connor PM, Paull KD, Friend SH and Weinstein JN . (1998). Mol. Pharmacol., 53, 241–251.

  • Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK and Iacopetta BJ . (1996). Hum. Pathol., 27, 1050–1055.

  • Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N and Ohashi M . (1999). Anticancer. Res., 19, 3099–3108.

  • Sugikawa E, Tsunoda S, Nakanishi N and Ohashi M . (2002). Anticancer Res., 21, 2671–2675.

  • Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, Midgley CA and Lane DP . (1995). Oncogene., 10, 389–393.

  • Wieczorek AM, Waterman JL, Waterman MJ and Halazonetis TD . (1996). Nat. Med., 2, 1143–1146.

  • Wu X, Bayle JH, Olson D and Levine AJ . (1993). Genes Dev., 7, 1126–1132.

  • Zhang W, Guo XY, Hu GY, Liu WB, Shay JW and Deisseroth AB . (1994). EMBO J., 13, 2535–2544.

Download references

Acknowledgements

We thank Dr Farzan Rastinejad for the CP31398 compound, Dr Hua Lu for providing purified p53, and the Molecular Biology Core of Moffitt Cancer Center for real-time PCR analysis. We are also grateful to Dr Robert Schultz for providing ellipticine and its derivatives. This work was supported by grants from the American Cancer Society and National Institutes of Health to J Chen.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jiandong Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peng, Y., Li, C., Chen, L. et al. Rescue of mutant p53 transcription function by ellipticine. Oncogene 22, 4478–4487 (2003). https://doi.org/10.1038/sj.onc.1206777

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206777

Keywords

This article is cited by

Search

Quick links